Payment overview · 2025
General Payments
$2,676.34
128 reported records · 21 companies
Healthcare provider profile · identity verified
James Gerald Hardigan, DO, PHARM D
Allopathic & Osteopathic Physicians|Family Medicine · LAKELAND, FL · NPI 1649231127
Verified facts
What the public records show
CMS Open Payments records show James Gerald Hardigan, DO, PHARM D received $2,676.34 in general payments during 2025 across 128 reported records.
Novo Nordisk Inc accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 369 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $651.28 | 24.3% | 30 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $424.85 | 15.9% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $272.82 | 10.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.16 | 6.0% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $152.08 | 5.7% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.28 | 5.2% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $137.66 | 5.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.33 | 4.3% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.27 | 4.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $100.11 | 3.7% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $85.91 | 3.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $68.34 | 2.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.84 | 2.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.59 | 1.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.07 | 1.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.96 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.69 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.18 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.68 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.45 | 0.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.79 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,676.34 | 128 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $475.85 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $384.32 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $200.46 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $189.43 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $175.43 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $133.83 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $114.72 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $114.72 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $111.27 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $102.73 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.73 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $100.11 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $93.89 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.62 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.55 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $76.75 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.58 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $68.34 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.90 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $64.70 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.43 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $44.86 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.69 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.33 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $30.96 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 353 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 157 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 196 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 369 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 18 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
117 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
157 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 40 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
353 | 94 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
196 | 38 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
369 | 82 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
353 | 94 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1171 | 350 |
| Amlodipine Besylate | Amlodipine Besylate | 1016 | 289 |
| Levothyroxine Sodium | Levothyroxine Sodium | 845 | 232 |
| Lisinopril | Lisinopril | 839 | 240 |
| Losartan Potassium | Losartan Potassium | 711 | 221 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 648 | 200 |
| Pantoprazole Sodium | Pantoprazole Sodium | 561 | 167 |
| Gabapentin | Gabapentin | 558 | 167 |
| Famotidine | Famotidine | 490 | 152 |
| Tamsulosin Hcl | Tamsulosin Hcl | 488 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 478 | 145 |
| Omeprazole | Omeprazole | 457 | 134 |
| Ozempic | Semaglutide | 369 | 82 |
| Escitalopram Oxalate | Escitalopram Oxalate | 361 | 116 |
| Furosemide | Furosemide | 357 | 127 |
| Eliquis | Apixaban | 353 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 339 | 99 |
| Trazodone Hcl | Trazodone Hcl | 335 | 100 |
| Metformin Hcl | Metformin Hcl | 327 | 109 |
| Tramadol Hcl | Tramadol Hcl | 309 | 87 |
| Alprazolam | Alprazolam | 305 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 301 | 96 |
| Simvastatin | Simvastatin | 296 | 89 |
| Carvedilol | Carvedilol | 280 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 270 | 72 |
| Methylprednisolone | Methylprednisolone | 266 | 210 |
| Ezetimibe | Ezetimibe | 241 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 228 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 224 | 60 |
| Sertraline Hcl | Sertraline Hcl | 222 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 211 | 64 |
| Montelukast Sodium | Montelukast Sodium | 206 | 61 |
| Prednisone | Prednisone | 203 | 151 |
| Finasteride | Finasteride | 198 | 54 |
| Potassium Chloride | Potassium Chloride | 197 | 58 |
| Mounjaro | Tirzepatide | 196 | 38 |
| Glipizide Er | Glipizide | 194 | 59 |
| Celecoxib | Celecoxib | 189 | 56 |
| Allopurinol | Allopurinol | 187 | 60 |
| Azithromycin | Azithromycin | 176 | 150 |
| Hydralazine Hcl | Hydralazine Hcl | 176 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 48 |
| Bupropion Xl | Bupropion Hcl | 157 | 49 |
| Farxiga | Dapagliflozin Propanediol | 157 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 56 |
| Clonazepam | Clonazepam | 149 | 32 |
| Jardiance | Empagliflozin | 148 | 40 |
| Atenolol | Atenolol | 146 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 144 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 141 | 41 |
| Chlorthalidone | Chlorthalidone | 137 | 46 |
| Spironolactone | Spironolactone | 137 | 40 |
| Propranolol Hcl | Propranolol Hcl | 134 | 41 |
| Xarelto | Rivaroxaban | 122 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 33 |
| Synthroid | Levothyroxine Sodium | 117 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 117 | 33 |
| Lovastatin | Lovastatin | 116 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 39 |
| Cefuroxime | Cefuroxime Axetil | 113 | 102 |
| Repatha Sureclick | Evolocumab | 111 | 26 |
| Donepezil Hcl | Donepezil Hcl | 110 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 31 |
| Cephalexin | Cephalexin | 103 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 29 |
| Clonidine Hcl | Clonidine Hcl | 95 | 51 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 95 | 81 |
| Doxazosin Mesylate | Doxazosin Mesylate | 87 | 27 |
| Meloxicam | Meloxicam | 87 | 28 |
| Sucralfate | Sucralfate | 86 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 84 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 28 |
| Warfarin Sodium | Warfarin Sodium | 81 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 26 |
| Glipizide | Glipizide | 77 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 75 | 58 |
| Buspirone Hcl | Buspirone Hcl | 74 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 20 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 74 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 22 |
| Lorazepam | Lorazepam | 69 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 19 |
| Memantine Hcl | Memantine Hcl | 64 | 16 |
| Nitroglycerin | Nitroglycerin | 64 | 44 |
| Amoxicillin | Amoxicillin | 63 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 53 |
| Myrbetriq | Mirabegron | 61 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 46 |
| Pregabalin | Pregabalin | 59 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 18 |
| Colchicine | Colchicine | 58 | 21 |
| Vascepa | Icosapent Ethyl | 58 | 16 |
| Naproxen | Naproxen | 56 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 29 |
| Glimepiride | Glimepiride | 54 | 18 |
| Levofloxacin | Levofloxacin | 54 | 43 |
| Meclizine Hcl | Meclizine Hcl | 54 | 27 |
| Nifedipine Er | Nifedipine | 54 | 14 |
| Fluconazole | Fluconazole | 53 | 27 |
| Sildenafil Citrate | Sildenafil Citrate | 53 | 17 |
| Benazepril Hcl | Benazepril Hcl | 52 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 22 |
| Januvia | Sitagliptin Phosphate | 52 | 13 |
| Jantoven | Warfarin Sodium | 51 | 14 |
| Primidone | Primidone | 51 | 16 |
| Metformin Hcl Er | Metformin Hcl | 48 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 46 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 12 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 46 | 19 |
| Valacyclovir | Valacyclovir Hcl | 46 | 23 |
| Diazepam | Diazepam | 45 | 26 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 14 |
| Irbesartan | Irbesartan | 43 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 26 |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Fenofibrate | Fenofibrate | 41 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 40 | 13 |
| Gemtesa | Vibegron | 38 | 12 |
| Lansoprazole | Lansoprazole | 37 | 11 |
| Temazepam | Temazepam | 37 | 14 |
| Ibuprofen | Ibuprofen | 35 | 14 |
| Digoxin | Digoxin | 34 | 12 |
| Cilostazol | Cilostazol | 33 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Sotalol | Sotalol Hcl | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 18 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Valsartan | Valsartan | 29 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Nystatin | Nystatin | 23 | 13 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | 11 |
| Indomethacin | Indomethacin | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 15 |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,676.34 · 128 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Sunosi, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error